Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...

Cytokinetics (CYTK) on Monday shared new analyses related to aficamten’s effects associated with standard of care combination therapy and its ...

Cytokinetics (CYTK) announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...

New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with ...

Cytokinetics (CYTK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other oversold pharma stocks to buy according to analysts. On February 20 ...

Andrew Callos, the EVP of $CYTK, sold 3,341 shares of the company on 03-06-2025 for an estimated $144,565. We received data on the trade from a recent SEC filing ...

Arizona State Retirement System raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.9% during ...